Free Trial
NASDAQ:KNSA

Kiniksa Pharmaceuticals International (KNSA) Stock Price, News & Analysis

Kiniksa Pharmaceuticals International logo
$28.38 -0.68 (-2.34%)
Closing price 04:00 PM Eastern
Extended Trading
$28.38 0.00 (-0.02%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Kiniksa Pharmaceuticals International Stock (NASDAQ:KNSA)

Key Stats

Today's Range
$28.22
$29.23
50-Day Range
$20.02
$30.33
52-Week Range
$17.38
$30.69
Volume
584,625 shs
Average Volume
519,008 shs
Market Capitalization
$2.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.80
Consensus Rating
Buy

Company Overview

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Kiniksa Pharmaceuticals International Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

KNSA MarketRank™: 

Kiniksa Pharmaceuticals International scored higher than 64% of companies evaluated by MarketBeat, and ranked 342nd out of 931 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Kiniksa Pharmaceuticals International are expected to grow in the coming year, from ($0.55) to $0.25 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kiniksa Pharmaceuticals International is -113.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kiniksa Pharmaceuticals International is -113.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kiniksa Pharmaceuticals International has a P/B Ratio of 4.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Kiniksa Pharmaceuticals International's valuation and earnings.
  • Percentage of Shares Shorted

    8.29% of the float of Kiniksa Pharmaceuticals International has been sold short.
  • Short Interest Ratio / Days to Cover

    Kiniksa Pharmaceuticals International has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Kiniksa Pharmaceuticals International has recently decreased by 17.82%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Kiniksa Pharmaceuticals International does not currently pay a dividend.

  • Dividend Growth

    Kiniksa Pharmaceuticals International does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.29% of the float of Kiniksa Pharmaceuticals International has been sold short.
  • Short Interest Ratio / Days to Cover

    Kiniksa Pharmaceuticals International has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Kiniksa Pharmaceuticals International has recently decreased by 17.82%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Kiniksa Pharmaceuticals International has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Kiniksa Pharmaceuticals International this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    3 people have added Kiniksa Pharmaceuticals International to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Kiniksa Pharmaceuticals International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,101,029.00 in company stock.

  • Percentage Held by Insiders

    53.48% of the stock of Kiniksa Pharmaceuticals International is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    53.95% of the stock of Kiniksa Pharmaceuticals International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Kiniksa Pharmaceuticals International's insider trading history.
Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals International and its competitors with MarketBeat's FREE daily newsletter.

KNSA Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
Kiniksa pharma COO Tessari sells $489k in shares
Kiniksa pharma COO Tessari sells $489k in shares
See More Headlines

KNSA Stock Analysis - Frequently Asked Questions

Kiniksa Pharmaceuticals International's stock was trading at $19.78 at the beginning of the year. Since then, KNSA shares have increased by 43.5% and is now trading at $28.38.
View the best growth stocks for 2025 here
.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) released its earnings results on Tuesday, April, 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.09. The business's revenue for the quarter was up 72.5% compared to the same quarter last year.
Read the conference call transcript
.

Kiniksa Pharmaceuticals International (KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Kiniksa Pharmaceuticals International's top institutional shareholders include Vanguard Group Inc. (4.62%), Braidwell LP (2.69%), Acadian Asset Management LLC (1.42%) and Millennium Management LLC (1.16%). Insiders that own company stock include Sanj K Patel, Eben Tessari, John F Paolini, Michael R Megna, Mark Ragosa, Barry D Quart and Ross Moat.
View institutional ownership trends
.

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kiniksa Pharmaceuticals International investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
4/29/2025
Today
6/25/2025
Next Earnings (Estimated)
7/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KNSA
Fax
N/A
Employees
220
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.80
High Stock Price Target
$45.00
Low Stock Price Target
$34.00
Potential Upside/Downside
+36.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.19 million
Pretax Margin
-1.31%

Debt

Sales & Book Value

Annual Sales
$423.24 million
Price / Cash Flow
N/A
Book Value
$6.60 per share
Price / Book
4.30

Miscellaneous

Free Float
33,946,000
Market Cap
$2.07 billion
Optionable
Optionable
Beta
0.06
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:KNSA) was last updated on 6/25/2025 by MarketBeat.com Staff
From Our Partners